Skip to main content

News

FDA Warns of Bone Fracture Risk and Lower BMD with Diabetes Drug

The FDA has strengthened its warnings for the type 2 diabetes drug canagliflozin (Invokana, Invokamet) and the apparent increased risk of bone fractures, and added new information about decreased bone mineral density.

Antibodies to 14-3-3η Found in Large Vessel Vasculitis

14-3-3η (eta) is a new test that may be useful in diagnosing patients with early rheumatoid arthritis. The test is 77% sensitive and 93% specific for RA and developers have found that antibodies against 14-3-3η may correlate with drug responsiveness.

Arthritis and Poverty: Chicken or Egg?

The development of arthritis is an underappreciated reason why individuals become impoverished -- a finding that was particularly pronounced for women, an Australian study found.

JIA Pathogenesis Related to Neutrophils and Epigenetics

Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).

High False Negative Rate with PFTs in Scleroderma

Researchers in Zurich studed 102 systemic sclerosis with serial PFTs and high-resolution computed tomography of the chest (HRCT). They found significant interstitial lung disease (ILD) by HRCT in 63 percent.

Obesity Protects Men from Rheumatoid Arthritis

Researchers from Malmo, Sweden have analyzed data from 383 patients, taken from two population based health surveys with a total of 50,705 participants, and found there is a strong association between a high BMI in men and a lower risk of developing rheumatoid arthritis (RA).

Higher Death Rates in Ankylosing Spondylitis

A nationwide study of 8600 ankylosing spondylitis (AS) patients from Sweden, compared survival to 40,460 controls between 2006-2012.

Education of the Fibromyalgia Patient

This week's Daily Download is the fibromyalgia “packet” we give to our patients once they have been diagnosed with fibromyalgia.

Overuse and Underuse of Osteoporosis Drugs

A population-based sudy 824 post-menopausal women ≥50 years old from Valencia, Spain was studied to estimate the percentage of women eligible for treatment, and the proportion of overuse and underuse of antiosteoporotic treatment according to highly-influentia

Shingles Vaccine Not Cost-Effective in Those Under 60

The herpes zoster (HZ- shingles) vaccine was FDA approved for use in individuals over age 50 years.  However, the CDC Advisory Committee on Immunization Practices (ACIP) has recommended it only be used in those over age 60 years.  

Drug Safety Reports & FDA Updates – August 2015

Safety reports from literature include long-term safety of rituximab, rituximab-induced neutropenia, tabalumab (Anti-BAFF Mab) results from the ILLUMINATE trial, colchicine toxicity increased in CKD patients, FDA updates and drug labeling changes, and more.

Serious Infections Increased in Etanercept-Treated Juvenile Arthritis Patients

UK researchers set out to study medically significant infections (MSI) in juvenile idiopathic arthritis patients enrolled in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).

More Knee Replacements at Younger Ages

The National Hospital Discharge Survey shows that between 2000 and 2010, more than 5.2 million total knee replacements were performed in the United States. By 2010, the operation had become the leading inpatient surgery performed on adults aged 45 and over.

SCOT Study Shows NSAID Safety

Since the 2005 FDA hearing that resulted in the removal of Vioxx and Bextra from the US market, the safety of nonselective NSAIDs (nsNSAIDs) and selective Cox-2 inhibitors (e.g., celecoxib) has been repeatedly questioned, often without new or substantive data.

Hospitalized Infections are Higher with the Second Biologic

Using Medicare claims data on 189,326 RA patients, researchers at the University of Alabama at Birmingham examined the rates of hospitalized infections in previously biologic-treated RA patients and compared rates in cohorts starting new treatment with etanercept, adalimumab, certolizum

×